stockrowUnited Therapeutics Corporation
UTHR Healthcare Drug Manufacturers Specialty & Generic
United Therapeutics Corporation’s revenue for fiscal 2025 (year ended December 2025) was $3.2 billion, up 10.6% from fiscal 2024.
- Revenue
- +4.13%
- EPS
- −21.7%
- Free cash flow
- −63.7%
Quarter to September 2026, against a year earlier
Follow UTHR
Alert me
United Therapeutics Corporation (UTHR) Revenue growth
United Therapeutics Corporation's revenue growth over the twelve months to 30 September 2026 was 1.89%, down 8.7 percentage points from fiscal 2025 (10.6%). Over the past ten years it has ranged from −11.0% (fiscal 2019) to 23.6% (fiscal 2024); the current reading is higher than 55% of that period. That is below the Drug Manufacturers Specialty & Generic industry median of 5.22% and below the Healthcare sector median of 7.80%.
Revenue growth, annual
Embed this chart
Annual newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | 10.6% | (13.02) |
| FY2024 | 23.6% | 3.43 |
| FY2023 | 20.2% | 5.32 |
| FY2022 | 14.9% | 1.25 |
| FY2021 | 13.6% | 11.25 |
| FY2020 | 2.38% | 13.38 |
| FY2019 | −11.0% | (5.35) |
| FY2018 | −5.65% | (13.56) |
| FY2017 | 7.91% | (1.16) |
| FY2016 | 9.07% | (4.69) |
Quarterly newest first
| Period | Revenue growth | Change (points) |
|---|---|---|
| Sep 2026 | 4.13% | 6.05 |
| Jun 2026 | −1.92% | (0.30) |
| Mar 2026 | −1.62% | (9.00) |
| Dec 2025 | 7.38% | 0.62 |
| 43 more quarters | Free account |
Against its own ten years
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| NBIX Neurocrine Biosciences, Inc. compare | 38.0% |
| ELAN Elanco Animal Health Incorporated compare | 12.0% |
| VTRS Viatris Inc. compare | 4.27% |
| TEVA Teva Pharmaceutical Industries Ltd. compare | 2.71% |
| UTHR United Therapeutics Corporation | 1.89% |
| ZTS Zoetis Inc. compare | 1.58% |
| TAK Takeda Pharmaceutical Co. compare | 0.66% |
| RDY Dr. Reddy's Laboratories Ltd compare | −15.5% |
| HLN Haleon PLC Sponsored ADR compare | — |
| Drug Manufacturers Specialty & Generic industry median | 5.22% |
| Healthcare sector median | 7.80% |
| Market median | 7.58% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on UTHR
- Revenue
- Net income
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement